Barrett’s esophagus is a precursor to esophageal cancer, with early detection improving survival rates significantly. Definitions of Barrett’s esophagus vary, impacting esophageal cancer detection ...
Lenvima and Keytruda with chemotherapy did not significantly improve OS in metastatic ESCC compared to Keytruda and chemotherapy alone. Median OS was 17.6 months in the Lenvima arm versus 15.5 months ...
IN THIS MORNING’S MEDICAL ALERT, APRIL IS ESOPHAGEAL AWARENESS MONTH. AND HERE TO TELL US ABOUT THE DISEASE, WHO IT AFFECTS, AND THE WARNING SIGNS IS PRESIDENT AND CEO OF THE ESOPHAGEAL CANCER ACTION ...
SAN FRANCISCO -- Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with ...
On Friday, Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESAIY) (OTC:ESALF) announced results from the Phase 3 LEAP-015 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib), in combination ...
Combination therapy with cadonilimab, a first-in-class bispecific antibody targeting both PD-1 and CTLA-4, and chemotherapy offers encouraging antitumor activity and manageable safety as a first-line ...
HARRISBURG, Pa. — Through a partnership with Lucid Diagnostics, the Harrisburg Bureau of Fire hosted a “Check Your Food Tube” screening event to test firefighters for Barrett’s Esophagus, a condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback